Interpersonal Communication and Vaccination Workflow Training in Pharmacies to Improve HPV Vaccination Recommendations
Official title: Implementing a Proactive Approach to Communicate and Teach About HPV Vaccination in Pharmacies: IMPACT HPV Study
Run by Fred Hutchinson Cancer Center · NCT06926062 · Data updated 2026-11-12
We’re testing whether training pharmacy staff in effective communication and vaccination workflows helps them recommend and provide HPV vaccines more consistently.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1900 (estimated) |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Locations | 2 sites (University Park, Pennsylvania and 1 other locations) |
| Status | Recruiting |
| Started | December 1, 2026 |
| Main results expected | August 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT06926062 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18+ who are parents or guardians of children aged 9–17 and English-speaking, residing in the U.S., plus pharmacy staff at participating sites.
✕Probably not a fit
Non-English speakers or those without eligible children in the 9–17 age range may not benefit from the current materials or procedures.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares usual pharmacy care to two training approaches—interpersonal communication training, vaccination workflow training, or both—to see which improves how pharmacy staff advise on HPV vaccination. The trial uses a multi-arm design with pharmacy sites randomized to different training and workflow conditions. Adults who are parents of children aged 9–17 in the U.S. complete surveys, while participating pharmacies and staff are assessed on vaccination practices. The intervention builds on the 5 A’s communication framework and targets real-world pharmacy settings to boost HPV vaccination uptake. English-language materials are provided, and outcomes include messaging quality, staff behavior, and vaccination recommendations.
Why it matters
Potential benefit: If successful, the training could help pharmacy staff consistently recommend HPV vaccination and streamline vaccination workflows, potentially increasing vaccination rates.
How similar studies have gone: Other settings with proactive communication have shown improvements, but applying this in pharmacies is novel and largely untested prior to this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * OBJECTIVE 1: Adults aged 18 years or older who live in the 50 United States (U.S.) states and Washington District of Columbia (D.C.) and are parents or guardians of children ages 9-17 are eligible to take the national survey (n ≤ 1,600, with anticipated enrollment of n = \~1,500) * OBJECTIVE 2: Pharmacy staff at participating pharmacies (n ≤ 100) * OBJECTIVE 2: Adults aged 18 years or older whose children ages 9-17 received an HPV vaccine at one of the participating pharmacies in study year 2 (n ≤ 200) Exclusion Criteria: * OBJECTIVE 1: Non-English speaking as the survey is only available for this project in English * OBJECTIVE 1: Parents whose index children have completed the HPV vaccine series * OBJECTIVE 2: Non-English speaking as the study funding only provided resources for surveys and interview materials to be available in English * OBJECTIVE 2: Parents whose index children have completed the HPV vaccine series
Where it's running
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States Recruiting -
Penn State University
University Park, Pennsylvania, United States Not yet recruiting
Study contacts
- Principal investigator: Parth Shah, PharmD, PhD — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Morgan Glascock
- Email: mglascoc@fredhutch.org
- Phone: 206-667-7438
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TweenVax: a program to increase HPV vaccination in 9–12-year-olds
This project tests whether the TweenVax program—education and messaging for clinics, providers, parents, and patients—helps more unvaccinated 9–12-year-olds start the HPV vaccine series than usual care.
-
Testing a new vaccine to prevent HPV-related cancers in women
This study is testing a new vaccine to see if it can safely prevent HPV-related cancers in women aged 18 to 45.
-
Telehealth pharmacist-led opioid education for cancer patients
This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.
-
Feasibility of using SmartMatch for guiding treatment options in rare gynecologic cancers
This observational study tests whether SmartMatch analysis on tissue from standard surgeries or biopsies can help identify treatment options for adults with advanced rare gynecologic cancers.
-
Enfortumab Vedotin, Pembrolizumab, and Quemliclustat for unresectable or metastatic urothelial cancer
This trial tests a three-drug combination to see if it can safely treat unresectable or metastatic urothelial cancer in adults.
-
WT1-targeted TCR T cells with azacitidine for AML with minimal residual disease
This phase 1 trial tests whether giving a patient’s own WT1-specific T cells together with azacitidine is safe and can help treat AML with MRD positivity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.